Scilligence is pleased to announce the grand opening of its San Francisco office on February 17th, 2020! Our new location is 395 Oyster Point Blvd, Suite 209, San Francisco. We look forward to better serving our clients in the West Coast.
Our colleagues will be at Bio-IT West/Tri-Con (Booth #824) from March 1-4. Stop by and ask about our integrated solutions for life science R&D or about ...
Read More
The Scilligence Weekly Issue No. 18
eGenesis, a Cambridge-based startup, is addressing the shortage of available organs for transplant by developing effective human transplantable organs using CRISPR technology to modify pig organs.
Read More
Are you curious about the relationship between genetics and memory, attention, and reaction speed? Online brain game company, Lumosity, and George Church’s Harvard research team have joined...
Read More
The Scilligence Weekly Issue No. 17
Global researchers have programmed computers to project odor based on a molecule. This feat in machine learning may change the future of the fragrance industry.
Read More
The Boston-based startup, Exonics Therapeutics is currently working on gene therapy and editing treatments to develop a treatment for Duchenne Muscular Dystrophy.
Read More
Harvard University tenured professor plans on ru...
Read More
The Scilligence Weekly Issue No. 16
Are you wondering how mussels stick to the shores of Boston beaches? Studies suggest the sticky protein mussels use to adhere to underwater rocks is caused by cation-π interactions between amino acids.
Read Article
Rhythm, a Boston biopharmaceutical company, receives financing to expand efforts in genetic obesity clinical trials. The proceeds are going to work on peptide drug, Setmelanotide.
...
Read More
The Scilligence Weekly Issue No. 15
News
Using cultured mouse embryonic stem cells, researchers at Boston University produced thyroid cells, which may be used as a base model for studying the possible causes of thyroid diseases.
Read Article
Cambridge-based Moderna Therapeutics gives insight into new drugs and vaccines they are currently developing.
Read Article
Chemists at The Scripps Research Institute (TSRI) have created...
Read More
The Scilligence Weekly Issue No. 14
News
A new synthetic system may allow the programming of cell phones and other microelectronic devices to identify and treat disease.
Read Article
Johns Hopkins researchers have discovered a peptide that doubles the effect time of the Wet AMD drug. The new discovery will increase the quality of life for patients by reducing the number of required injections.
Read Article
NIH funds researc...
Read More
Shanghai Hengrui Pharmaceutical Co., Ltd. has licensed Scilligence ELN
January 12, 2016
Shanghai Hengrui Pharmaceutical Co., Ltd. has licensed Scilligence ELN
Shanghai Hengrui Pharmaceutical Co., Ltd., a subsidiary of Jiangsu Hengrui Medicine Co., Ltd, has licensed Scilligence ELN (Electronic Laboratory Notebook) as a company-wide platform for their drug discovery and development effort. This State-of-the-art ELN platform will empower more efficient collaborations ...
Read More
The Scilligence Weekly Issue No. 13
This week’s roundup of science news and local job openings.
News
? Scientists have found how plants make cholesterol. The research conducted on tomatoes can provide a pathway to new discoveries in synthetic biology.
Read Article
Hair follicles may be the secret to reducing scar tissue. Growing hair follicles contain proteins that can develop the fat cells that fibrous tissue lacks.
Re...
Read More
Shanghai Syn-The-All Pharmaceutical Co. Ltd. (STA) has licensed Scilligence ELN
Shanghai Syn-The-All Pharmaceutical Co. Ltd. (STA) has licensed Scilligence ELN
Shanghai Syn-The-All Pharmaceutical Co. Ltd. (STA), a subsidiary of WuXi AppTec, has licensed Scilligence ELN (Electronic Laboratory Notebook) as a company-wide platform. This is yet another major collaboration since WuXi AppTec’s Chemistry Service Unit first implemented Scilligence ELN more than 3 years ago.
...
Read More
The Scilligence Weekly Issue No. 12
This week's roundup of latest advancements in research, new local job postings, and something fun!
News
With the world population aging, more and more people are becoming non-responsive to the hepatitis B vaccine. A third generation hepatitis B vaccine may provide more opportunities for the immune system to respond to antibodies in elderly people.
Read More
Cambridge-based Goldfinch Bio is ...
Read More